Navigation Links
CryoLife Posts Record Annual Revenues of $116.6 Million
Date:2/17/2011

ny does not believe that it will be able to distribute.  Excluding these charges, adjusted net income for the full year of 2010 was $9.5 million, or $0.34 per basic and fully diluted common share.

The Company recorded pretax charges in the full year of 2010 of approximately $1.4 million in costs related to litigation with Medafor, approximately $1.0 million related to business development activities, and $729,000 related to the write-off of capitalized legal expenses associated with BioGlue® Surgical Adhesive intellectual property rights in Germany.  Additionally, the Company recorded a $1.3 million gain on valuation of the derivative related to the investment in Medafor common stock.

Preservation service revenues for the fourth quarter of 2010 increased 2 percent to $14.0 million compared to $13.8 million for the fourth quarter of 2009.  Preservation service revenues for the full year of 2010 increased 6 percent to $59.7 million compared to $56.5 million for the full year of 2009.  The increase in preservation service revenues for the fourth quarter of 2010 was primarily due to increased shipments of cardiac tissues.  The increase in preservation service revenues for the full year of 2010 was primarily due to increased shipments of cardiac and vascular tissues.  

Product revenues, which consist primarily of sales of BioGlue, HemoStase, and PerClot, were $15.1 million for the fourth quarter of 2010 compared to $14.5 million for the fourth quarter of 2009, an increase of 4 percent.  Product revenues were $56.4 million for the full year of 2010 compared to $54.2 million for the full year of 2009, an increase of 4 percent.  The increase in product revenues was primarily due to an increase in HemoStase revenues and, to a lesser extent, the addition of PerClot revenues in the fourth quarter of 2010.

Total gross margins were 60 percent and 61 percent for the fourth quarters of 2010 and 2009, respecti
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. CryoLife Announces Release Date and Teleconference Call Details for 2010 Fourth Quarter and Year End Financial Results
2. CryoLife to Present at Lazard Capital Markets 7th Annual Healthcare Conference
3. CryoLife Begins Distribution of Blood-Clotting Agent PerClot® in Europe
4. CryoLife Announces Release Date and Teleconference Call Details for 2010 Third Quarter Financial Results
5. CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive
6. CryoLife Enters into Worldwide Distribution and Manufacturing Agreements with Starch Medical for Novel Hemostatic Agent
7. CryoLife Provides Initial 2010 Financial Guidance
8. CryoLife to Present at 21st Annual Piper Jaffray Health Care Conference
9. CryoLife to Present at Upcoming Investor Conferences in New York
10. CryoLife Reports Record Quarterly Revenues of $28.2 Million
11. CryoLife Receives FDA Approval to Begin U.S. Clinical Trial for BioFoam(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 Valeritas, Inc., ... designed for patients with Type 2 diabetes, announced today ... Chain Excellence Award. The award was presented October 16 ... Columbus, Ohio . ... judged across a variety of metrics specifically targeted at ...
(Date:10/20/2014)... 20, 2014   Taiho Oncology, Inc. , ... Japan ), announced that the U.S. ... designation for TAS-102 (nonproprietary names: trifluridine and tipiracil ... for the treatment of refractory metastatic colorectal cancer ... rolling NDA submission to the FDA. According to ...
(Date:10/20/2014)... 20, 2014   Mary,s Medicinals today announced ... a 4-Star Sponsor of Operation Grow4Vets , a ... products, programs and services to assist them in living ... Key Facts: , An ever-increasing number of ... and effective treatment for pain, Post-traumatic Stress Disorder (PTSD) ...
Breaking Medicine Technology:Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3
... Trial for the Treatment of Pediatric Eosinophilic Esophagitis , ... Cephalon, Inc . (Nasdaq: CEPH ) and ... announced that the companies have signed an agreement providing ... stock of Ception. Under the terms of the ...
... of treatment, RAD001 halted tumor growth in 55% of ... Based on these promising data, Novartis will initiate a ... patients- Gastric cancer is the second leading cause of ... occurring in East AsiaEAST HANOVER, N.J., Jan. 13 ...
Cached Medicine Technology:Cephalon Signs Option Agreement to Acquire Ception Therapeutics 2Cephalon Signs Option Agreement to Acquire Ception Therapeutics 3Cephalon Signs Option Agreement to Acquire Ception Therapeutics 4RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 2RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 3RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 4RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 5RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 6
(Date:10/20/2014)... 2014 Unveiled at the Sept. 18 board ... conservatively estimates member hospital ROI on membership dues at 12.5. ... Center provides $12.50 in value to member hospitals. The calculation ... Member Dues)/Member Dues. , “This is the first time ... we think the methodology is really sound,” said Bill ...
(Date:10/20/2014)... USA (PRWEB) October 20, 2014 Do ... track interventions? Here comes a wonderful app Metassessor for ... app development company helped its client “Intervention Development ... efficiently. The app is designed for iOS 4.3 or ... touch. This app is optimized for iPhone 5. It ...
(Date:10/19/2014)... York (PRWEB) October 19, 2014 Dr. ... Population Fund, welcomes news of a ceasefire agreement that ... more than 200 girls who were kidnapped from the ... have languished in captivity long enough, and it is ... and communities," stated Dr. Osotimehin. , "We owe it ...
(Date:10/19/2014)... Fancyflyingfox.com, an innovative company that provides many kinds of ... of 2014 mother of the bride dresses . ... with big discounts, up to 70% off. All consumers ... this special offer. , Owing to the company’s ... of the leading brands in the global market. A ...
(Date:10/19/2014)... (HealthDay News) -- New stem cell-based research could improve ... treatments, a new study suggests. Scientists used stem ... in a lab dish. They then transplanted the organoids ... disorders, according to the researchers. "This provides a ... that can cause intestinal failure, from genetic disorders appearing ...
Breaking Medicine News(10 mins):Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2
... the Bench,-, EL SEGUNDO, Calif., Oct. 16 ... solutions for microarray-based,research, announced today the release of ... that provides easy, fast and powerful platform,independent and ... data sets, simultaneously. NEXUS CGH easily supports ...
... The department of bioengineering at Clemson University has received ... Both the National Institutes of Health (NIH) and a ... (NSBRI www.nsbri.org ), are primary contributors of funds ... application. , The study addresses bone loss that occurs ...
... YORK, Oct. 16 Even though Americans pick up ... toothbrushes,may need a cleaning of their own. Celebrity Dentist ... says a new survey conducted by the,Philips Sonicare brand ... Listen to this report from Philips (NYSE: ...
... Unique Request Highlights December 2 Annual Wells Fargo Walk of Ages ... ... Home is,inviting everyone with the name of "Walker" in the United States to ... Walk of,Ages" on December 2 in Reseda. According to official census records there,are ...
... - BCL.P, VANCOUVER, Oct. 16 /PRNewswire-FirstCall/ ... announce that it has entered into an ... (the "Arrangement,Agreement") with iCo Therapeutics Inc. ("iCo"). ... constitute Beanstalk,s,"Qualifying Transaction" as a capital pool ...
... children appear to have a lower risk of asthma ... a non-agricultural rural environment, according to a University of ... 13,524 asthmafree children aged less than 12 years in ... Youth (NLSCY) showed that children living in a farming ...
Cached Medicine News:Health News:BioDiscovery Releases NEXUS CGH Version 2 for DNA Copy Number Analysis and Visualization 2Health News:Clemson awarded $2M to study radiation-induced bone loss 2Health News:FORGET THE JONESES, This is All About Keeping up With the Walkers as the Los Angeles Jewish Home Sends Out an Invite to Everyone Named 'Walker' in the United States 2Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 2Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 3Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 4Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 5Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 6Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 7Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 8Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 9Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 10Health News:Farm kids have lower risk of asthma, study shows 2
Double Ended Occluders...
Designed to provide occlusion while permitting observation of the eye. Helpful to determine if only one eye is deviating. Approximately 9 inches long....
Long handle occluders are approximately 9 inches long....
Long handle occluders are approximately 9 inches long....
Medicine Products: